1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

myeloid/T cell coculture

" in MedChemExpress (MCE) Product Catalog:

9539

Inhibitors & Agonists

180

Screening Libraries

483

Fluorescent Dye

238

Biochemical Assay Reagents

870

Peptides

87

MCE Kits

314

Inhibitory Antibodies

1595

Natural
Products

1390

Recombinant Proteins

403

Isotope-Labeled Compounds

221

Antibodies

84

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99390

    MCLA 117

    CD3 Cancer
    Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .
    Tepoditamab
  • HY-P9947

    Integrin Others
    Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
    Efalizumab
  • HY-130625

    PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN 6 (compound A13) is a potent PD-1/PD-L1 interaction inhibitor, with an IC50 of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model .
    PD-1/PD-L1-IN 6
  • HY-161045

    EGFR Apoptosis Cancer
    T-1-DOCA ia a EGFR inhibitor, with the IC50 of 56.94 and 269.01?nM for EGFR WT and EGFR T790M, respectively. T-1-DOCA can induces cell apoptosis of HCT-116 cells .
    <em>T</em>-1-DOCA
  • HY-149981

    P-glycoprotein Cancer
    P-gp inhibitor 13 is a P-gp inhibitor. P-gp inhibitor 13 can reverse P-glycoprotein-mediated paclitaxel resistance in A2780/T cell. P-gp inhibitor 13 can be used for the research of advanced acute myeloid leukemia .
    P-gp inhibitor 13
  • HY-136498

    Drug Metabolite Infection
    T-705RMP, a phosphorylated metabolite of T-705, exhibits a very weak inhibitory effect on the IMP dehydrogenase (IMPDH) activities of the host cells, with an IC50 of 601 μM .
    <em>T</em>-705RMP
  • HY-P99521

    XmAb14045

    CD3 Cancer
    Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .
    Vibecotamab
  • HY-162045

    Others Cancer
    Ru-4T is a phototherapy agent. Ru-4T has phototherapeutic efficacy (PI = 114,000) against melanoma cells (SK-MEL-28) under broad-band visible light (400-700 nm) with EC50 values of 740 pM .
    Ru-4<em>T</em>
  • HY-123295

    HDAC Infection Cancer
    HDAC3-IN-T247 is a potent and selective HDAC3 (histone deacetylase 3) inhibitor, with an IC50 of 0.24 µM. HDAC3-IN-T247 induces a selective increase of NF-κB acetylation in HCT116 cells. HDAC3-IN-T247 shows anticancer and antiviral activity. HDAC3-IN-T247 inhibits growth of cancer cells, and activates HIV gene expression in latent HIV-infected cells .
    HDAC3-IN-<em>T</em>247
  • HY-125961

    Others Cancer
    T3Inh-1 is a potent and selective inhibitor of ppGalNAc-T3 (IC50=7 µM). T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects. T3Inh-1 also prevents breast cancer cells. The enzyme ppGalNAc-T3 is implicated in at least two medically important pathways: cancer metastasis and stabilization of FGF23 (regulates phosphate levels in the bloodstream) .
    <em>T</em>3Inh-1
  • HY-12083

    Bcr-Abl Cancer
    PPY-A is a potent T315I mutant and wild-type Abl kinases inhibitor with IC50s of 9 and 20 nM, respectively. PPY-A inhibits Ba⁄F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC50s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML) .
    PPY-A
  • HY-163064

    LRRK2 Cancer
    CC-3240 (compound 13) is a molecular glue degrader of CaMKK2 based on CC-8977, with the IC50 of 9 nM .
    CC-3240
  • HY-P99014
    Cusatuzumab
    1 Publications Verification

    Apoptosis Inflammation/Immunology
    Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .
    Cusatuzumab
  • HY-117233

    β-catenin Wnt Metabolic Disease Cancer
    UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) with a Ki of 1.36 μM . UU-T02 inhibits canonical Wnt signaling and the growth of colorectal cancer cells .
    UU-<em>T</em>02
  • HY-P9948

    Campath-IH

    Apoptosis Cancer
    Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
    Alemtuzumab
  • HY-P1404

    Pim Cancer
    R8-T198wt is a cell-permeable carboxyl-terminal p27 Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase .
    R8-<em>T</em>198wt
  • HY-145620

    ADC Linker Inflammation/Immunology Cancer
    Zuvotolimod is a myeloid cell agonist compound-linker for antibody conjugate. Zuvotolimod can be used in the research of cancer and hepatitis .
    Zuvotolimod
  • HY-W181026

    Others Inflammation/Immunology
    KLF10-IN-1 (#48-15) is a KLF10 inhibitor with an IC50 value of 40 μM against the KLF10 reporter gene. KLF10-IN-1 can suppress KLF10-DNA binding and transcriptional activity, block the conversion of CD4+CD25− T cells into CD4+CD25+ T regulatory cells, and downregulate the expression of KLF10 target genes. KLF10-IN-1 can be utilized as a useful mechanistic probe for studying KLF10-mediated effects and T regulatory cell biology .
    KLF10-IN-1
  • HY-110251
    DFHBI-1T
    5+ Cited Publications

    DNA Stain Others
    DFHBI-1T is a membrane-permeable RNA aptamers-activated fluorescence probe (ex/em=472 nm/507 nm). DFHBI-1T binds to RNA aptamers (Spinach, Spinach2, iSpinach, and Broccoli) and causes specific fluorescence and lower background fluorescence. DFHBI-1T is used to image RNA in live cells .
    DFHBI-1<em>T</em>
  • HY-P99392

    CD3 Cancer
    Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
    Teclistamab
  • HY-119527

    Others Inflammation/Immunology Cancer
    Conagenin is an immunomodulator. Conagenin shows antitumor effects by activation of T cells and increasing antitumor effector cells .
    Conagenin
  • HY-131140
    BD750
    2 Publications Verification

    JAK STAT Inflammation/Immunology Cancer
    BD750, an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC50 values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively .
    BD750
  • HY-144088

    HPK1-IN-22

    MAP4K Inflammation/Immunology Cancer
    ZYF0033 is effective in inhibiting hematopoietic progenitor cells HPK1, basically inhibiting MBP protein oxidation IC50 10 nM . ZYF0033 promotes anti-cancer immune response, lowers SLP76 (acid 376) oxidation. ZYF0033 Suppression 4T-1 Small mouse model with the same underlying cause, medium bulge growth length expansion DC, NK 细细和 CD107a + CD8 + T Cells, PD-1 +CD8 + T Cells, TIM-3 +CD8 + T Cells LAG3< sup>+CD8 + T Cellular immersion decreases.
    ZYF0033
  • HY-P99523

    AMG 199

    CD3 Cancer
    Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .
    Vepsitamab
  • HY-129592

    Apoptosis Cancer
    p-Tolylmaleimide (compound 9) is a naphthalimide derivative that has cytotoxic effects on cancer cells. p-Tolylmaleimide can arrest the cell cycle of human acute myeloid leukemia cells K562 in the sub-G0/G1 phase and induce apoptosis .
    p-Tolylmaleimide
  • HY-160053

    PDGFR Cancer
    Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .
    Gint4.<em>T</em> aptamer sodium
  • HY-19352
    T56-LIMKi
    1 Publications Verification

    T5601640

    LIM Kinase (LIMK) Cancer
    T56-LIMKi is a selective inhibitor of LIMK2; inhibits the growth of Panc-1 cells with an IC50 of 35.2 μM.
    <em>T</em>56-LIMKi
  • HY-126037
    (±)-ML 209
    1 Publications Verification

    ROR Inflammation/Immunology
    (±)-ML 209 (compound 4n), a diphenylpropanamide, is a retinoic acid-related orphan receptor RORγ antagonist with an IC50 of 1.1 μM. (±)-ML 209 inhibits RORγt transcriptional activity with an IC50 of 300 nM in HEK293t cells. (±)-ML 209 inhibits the transcriptional activity of RORγt, but not RORα in cells. (±)-ML 209 selectively inhibits murine Th17 cell differentiation without affecting the differentiation of naïve CD4 + T cells into other lineages, including Th1 and regulatory T cells .
    (±)-ML 209
  • HY-163028

    Tim3 Cancer
    ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .
    ML-<em>T</em>7
  • HY-125930

    Topoisomerase DNA/RNA Synthesis Cancer
    T-2513 is a selective topoisomerase I inhibitor. T-2513 binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death .
    <em>T</em>-2513
  • HY-125930A

    Topoisomerase DNA/RNA Synthesis Cancer
    T-2513 hydrochloride is a selective topoisomerase I inhibitor. T-2513 hydrochloride binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death .
    <em>T</em>-2513 hydrochloride
  • HY-P1430

    cell permeable NFAT inhibitor

    Nuclear Factor of activated T Cells (NFAT) Metabolic Disease
    11R-VIVIT is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT can be used for the research of podocyte and diabetic nephropathy .
    11R-VIVIT
  • HY-154961

    Bcl-2 Family Cancer
    Mcl-1 inhibitor 14 (Compound (Ra)-10) is an inhibitor of myeloid cell leukemia-1 (MCL-1) with an Ki of 0.018 nM and can be used for anticancer research .
    Mcl-1 inhibitor 14
  • HY-P99302

    Humanized Anti-CD28 Recombinant Antibody

    CD28 Inflammation/Immunology
    Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling .
    Lulizumab
  • HY-142102

    (+)-T988C

    Others Cancer
    T988C is a heptacyclic epidithiodioxopiperazine (ETP) natural product. T988C shows strong cytotoxicity to cultured P388 leukemia cells .
    <em>T</em>988C
  • HY-P99024

    RO7082859

    CD20 Cancer
    Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma .
    Glofitamab
  • HY-136498A

    Drug Metabolite Infection
    T-705RMP (ammonium) is the ammonium form of T-705RMP. T-705RMP (ammonium)’s the inhibition of IMP dehydrogenase (IMPDH) activity is weak .
    <em>T</em>-705RMP ammonium
  • HY-112218
    MIK665
    5+ Cited Publications

    S-64315

    Bcl-2 Family Cancer
    MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 (MCL1) inhibitor . MIK665 has an IC50 of 1.81 nM for MCL1 .
    MIK665
  • HY-D0070

    Diaminofluorescein 2T

    Fluorescent Dye Others
    DAF-2T (Diaminofluorescein 2T) is a multifunctional dye. Dyes are important tools in biological experiments. They can help researchers observe and analyze cell structures, track biomolecules, evaluate cell functions, distinguish cell types, detect biomolecules, study tissue pathology and monitor microorganisms. Their applications range from basic scientific research to clinical A wide range of diagnostics. Dyes are also widely used in traditional fields such as textile dyeing, as well as in emerging fields such as functional textile processing, food pigments and dye-sensitized solar cells.
    DAF-2<em>T</em>
  • HY-121662

    LDK

    Apoptosis Inflammation/Immunology Cancer
    Lenaldekar (LDK) inhibits human and murine T-cell expansiomn. Lenaldekar inhibits autoimmune T cell response. Lenaldekar also induces cancer cell apoptosis. Lenaldekar can be used for T-cell mediated autoimmune diseases research .
    Lenaldekar
  • HY-P99617

    REGN3767

    LAG-3 Cancer
    Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity .
    Fianlimab
  • HY-110251A

    DNA Stain Others
    DFHBI-2T is a membrane-permeable RNA aptamers-activated fluorescence probe (ex/em=500 nm/523 nm). DFHBI-2T is used to image RNA in live cells .
    DFHBI-2<em>T</em>
  • HY-162008

    HSP Bcl-2 Family Cancer
    S1g-10 is a Hsp70/Bim inhibitor, and shows antitumor activity in chronic myeloid leukemia cells .
    S1g-10
  • HY-P1430A
    11R-VIVIT TFA
    5+ Cited Publications

    cell permeable NFAT inhibitor TFA

    Nuclear Factor of activated T Cells (NFAT) Metabolic Disease
    11R-VIVIT TFA is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT TFA can be used for the research of podocyte and diabetic nephropathy .
    11R-VIVIT TFA
  • HY-103275

    NSC 680410

    Bcr-Abl Apoptosis Cancer
    Adaphostin (NSC 680410), the adamantyl ester of AG957, is a potent p210 bcr/abl inhibitor (IC50=14 μM). Adaphostin induces apoptosis in T-lymphoblastic human leukemia cell lines (IC50 ranging from 17 to 216 nM). Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Adaphostin increased the level of reactive oxygen species (ROS) within CLL B cells .
    Adaphostin
  • HY-101985
    BV02
    1 Publications Verification

    Bcr-Abl Cancer
    BV02 is a potent 4-3-3 PPI (14-3-3 protein–protein interaction) inhibitor. BV02 shows cytotoxicity for hematopoietic cells expressing the IM (imatinib mesylate)-sensitive wild type Bcr-Abl and the IM-resistant T315I mutation. BV02 has the potential for the research of chronic myeloid leukemia .
    BV02
  • HY-131183

    PROTACs PD-1/PD-L1 Inflammation/Immunology
    PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .
    PROTAC PD-1/PD-L1 degrader-1
  • HY-119339
    SX-682
    4 Publications Verification

    CXCR Inflammation/Immunology Endocrinology Cancer
    SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity .
    SX-682
  • HY-150751

    ODN A151

    Toll-like Receptor (TLR) AIM2 Inflammation/Immunology
    ODN TTAGGG (A151), inhibitory oligonucleotide (ODN), is a TLR9, AIM2 and cGAS antagonist. ODN TTAGGG is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3' .
    ODN TTAGGG
  • HY-160068

    EGFR Cancer
    2-2(t) aptamer sodium is a 42-nucleotide trimeric complex of aptamer (2-2) targeting ErbB-2. 2-2(t) aptamer sodium inhibits the growth of gastric cancer cells in vitro and in vivo .
    2-2(<em>t</em>) aptamer sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: